PESG Research releases a new market update on Silexion Therapeutics (NASDAQ: SLXN). Silexion recently announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer ...

The model used to ... This stands in contrast to subcutaneous xenograft models, where tumors grow beneath the skin rather than in the organ of origin. Importantly, orthotopic pancreatic models ...

This stands in contrast to subcutaneous xenograft models, where tumors grow beneath the skin rather than in the organ of origin. Importantly, orthotopic pancreatic models demonstrate metastatic ...